News

  • Positive results from enzalutamide study on metastatic prostate cancer patients

    The results of the Phase 3 Prevail Study on enzalutamide showed significant benefit to prostate cancer patients including delaying the progression of metastatic disease, reducing the risk of death and delaying the start of cytotoxic chemotherapy.

    Read more >

  • Plenary Session 4: Update and controversies in prostate cancer

    “The 29th EAU Congress has been a success. Particularly the attendance of countries beyond Europe was very high, for example Latin American countries like Brazil and Venezuela,” said Prof. Per-Anders Abrahmsson (Malmö, SE) in his opening remarks during the last Plenary Session of this year’s ...

    Read more >

  • Prof. Bob Djavan on the ambitions of the EAU Regional Office

    In this interview, Prof. Djavan talks about the role of the EAU Regional Office at #eau14 and its ambitious plans for the upcoming years.

    Read more >

  • Innovation in minimally-invasive techniques for the treatment of BPH

    Prof. Maurice Michel (Mannheim, DE) discussed the innovation in minimally-invasive treatment of BPH in Monday’s Thematic Session 11. This type of treatment can be done in an out-patient setting and is less invasive than surgical treatment.

    Read more >

  • Hands-on Training: Applying Botulinumtoxin A

    The application of Botulinum toxin A is still a budding area of expertise, and not without controversy, as could be seen in the heated debate at the Plenary Session of Day 4 of the EAU Congress in Stockholm. As part of the educational efforts of the European School of Urology (ESU) a small ...

    Read more >

  • Reconstructive Urology: The present and the future

    In a slightly adapted format due to the regretful absence of several speakers, Thematic Session 16 managed to convey a good look at the current state of reconstructive urology, as well as its future. In the words of the Session Chairman, Dr. René Yiou (FR): “The speakers gave a nice overview of ...

    Read more >

  • High-risk PCa: Urological or radiation oncological approach

    In the multidisciplinary Thematic Session 18, the urological and radiation oncological approaches to high-risk prostate cancer were discussed. The chairman of the session, Prof. Christian Stief (Munich, DE), introduced the debate by stating that the audience would hear “not necessarily opposing ...

    Read more >

  • Refractory problems in functional urology open Day 4 of the EAU Congress

    “What is needed is more involvement from urologists at the urodynamic lab,” said Prof. Paul Abrams (Bristol, GB), during the Société Internationale d’Urologie Lecture at Plenary Session 3. For him, the usefulness of urodynamics is still doubted by some not only because of the absence of ...

    Read more >

  • Recurrence of prostate cancer is significantly lower in men with blood group O

    A man’s blood group can affect the chance of a recurrence of prostate cancer after surgery, according to new research, which was presented at the European Association of Urology congress in Stockholm. This is the first time that this relationship has been demonstrated.

    Read more >

  • Thematic Session 10: Update on treatment options for patients with CRPC

    There are new treatment options for castration resistant prostate cancer (CRPC) but finding the optimal strategy and selecting the right patient is still fraught with challenges and difficulties, according to uro-oncology experts during a thematic session at the 29th Annual EAU Congress in ...

    Read more >

‹ 12345 ›
Sign in